Literature DB >> 19318498

Tiling path genomic profiling of grade 3 invasive ductal breast cancers.

Rachael Natrajan1, Maryou B Lambros, Socorro María Rodríguez-Pinilla, Gema Moreno-Bueno, David S P Tan, Caterina Marchió, Radost Vatcheva, Sydonia Rayter, Betania Mahler-Araujo, Laura G Fulford, Daniela Hungermann, Alan Mackay, Anita Grigoriadis, Kerry Fenwick, Narinder Tamber, David Hardisson, Andrew Tutt, Jose Palacios, Christopher J Lord, Horst Buerger, Alan Ashworth, Jorge S Reis-Filho.   

Abstract

PURPOSE: To characterize the molecular genetic profiles of grade 3 invasive ductal carcinomas of no special type using high-resolution microarray-based comparative genomic hybridization (aCGH) and to identify recurrent amplicons harboring putative therapeutic targets associated with luminal, HER-2, and basal-like tumor phenotypes. EXPERIMENTAL
DESIGN: Ninety-five grade 3 invasive ductal carcinomas of no special type were classified into luminal, HER-2, and basal-like subgroups using a previously validated immunohistochemical panel. Tumor samples were microdissected and subjected to aCGH using a tiling path 32K BAC array platform. Selected regions of recurrent amplification were validated by means of in situ hybridization. Expression of genes pertaining to selected amplicons was investigated using quantitative real-time PCR and gene silencing was done using previously validated short hairpin RNA constructs.
RESULTS: We show that basal-like and HER-2 tumors are characterized by "sawtooth" and "firestorm" genetic patterns, respectively, whereas luminal cancers were more heterogeneous. Apart from confirming known amplifications associated with basal-like (1q21, 10p, and 12p), luminal (8p12, 11q13, and 11q14), and HER-2 (17q12) cancers, we identified previously unreported recurrent amplifications associated with each molecular subgroup: 19q12 in basal-like, 1q32.1 in luminal, and 14q12 in HER-2 cancers. PPM1D gene amplification (17q23.2) was found in 20% and 8% of HER-2 and luminal cancers, respectively. Silencing of PPM1D by short hairpin RNA resulted in selective loss of viability in tumor cell lines harboring the 17q23.2 amplification.
CONCLUSIONS: Our results show the power of aCGH analysis in unraveling the genetic profiles of specific subgroups of cancer and for the identification of novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318498     DOI: 10.1158/1078-0432.CCR-08-1878

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  67 in total

Review 1.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

2.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  Absence of microsatellite instability in mucinous carcinomas of the breast.

Authors:  Magali Lacroix-Triki; Maryou B Lambros; Felipe C Geyer; Paula H Suarez; Jorge S Reis-Filho; Britta Weigelt
Journal:  Int J Clin Exp Pathol       Date:  2010-11-27

4.  Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.

Authors:  Jennifer A Byrne; Yuyan Chen; Nancy Martin La Rotta; Gregory B Peters
Journal:  Genes Cancer       Date:  2012-02

5.  Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes.

Authors:  Lorenzo Melchor; Laura Paula Saucedo-Cuevas; Iván Muñoz-Repeto; Socorro María Rodríguez-Pinilla; Emiliano Honrado; Alfredo Campoverde; Jose Palacios; Katherine L Nathanson; María José García; Javier Benítez
Journal:  Breast Cancer Res       Date:  2009-12-08       Impact factor: 6.466

6.  High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Authors:  Johan Staaf; Göran Jönsson; Markus Ringnér; Johan Vallon-Christersson; Dorthe Grabau; Adalgeir Arason; Haukur Gunnarsson; Bjarni A Agnarsson; Per-Olof Malmström; Oskar Th Johannsson; Niklas Loman; Rosa B Barkardottir; Ake Borg
Journal:  Breast Cancer Res       Date:  2010-05-06       Impact factor: 6.466

7.  Genome profiling of ERBB2-amplified breast cancers.

Authors:  Fabrice Sircoulomb; Ismahane Bekhouche; Pascal Finetti; José Adélaïde; Azza Ben Hamida; Julien Bonansea; Stéphane Raynaud; Charlène Innocenti; Emmanuelle Charafe-Jauffret; Carole Tarpin; Farhat Ben Ayed; Patrice Viens; Jocelyne Jacquemier; François Bertucci; Daniel Birnbaum; Max Chaffanet
Journal:  BMC Cancer       Date:  2010-10-08       Impact factor: 4.430

8.  Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

Authors:  María M Caffarel; Clara Andradas; Emilia Mira; Eduardo Pérez-Gómez; Camilla Cerutti; Gema Moreno-Bueno; Juana M Flores; Isabel García-Real; José Palacios; Santos Mañes; Manuel Guzmán; Cristina Sánchez
Journal:  Mol Cancer       Date:  2010-07-22       Impact factor: 27.401

Review 9.  Histological and molecular types of breast cancer: is there a unifying taxonomy?

Authors:  Britta Weigelt; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2009-12       Impact factor: 66.675

10.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

Authors:  N Turner; M B Lambros; H M Horlings; A Pearson; R Sharpe; R Natrajan; F C Geyer; M van Kouwenhove; B Kreike; A Mackay; A Ashworth; M J van de Vijver; J S Reis-Filho
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.